Merck KGaA (MKKGY)
Market Cap | 59.60B |
Revenue (ttm) | 21.90B |
Net Income (ttm) | 2.88B |
Shares Out | n/a |
EPS (ttm) | 6.61 |
PE Ratio | 20.73 |
Forward PE | n/a |
Dividend | 0.32 (1.17%) |
Ex-Dividend Date | Apr 29, 2025 |
Volume | 100 |
Average Volume | 163,589 |
Open | 27.09 |
Previous Close | 27.39 |
Day's Range | 27.09 - 27.24 |
52-Week Range | 24.32 - 39.17 |
Beta | 0.70 |
RSI | 51.99 |
Earnings Date | May 15, 2025 |
About Merck KGaA
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing a... [Read more]
Full Company ProfileFinancial Performance
In 2024, Merck KGaA's revenue was 21.16 billion, an increase of 0.78% compared to the previous year's 20.99 billion. Earnings were 2.78 billion, a decrease of -1.66%.
Financial numbers in EUR Financial StatementsNews

Merck KGaA: Still A Bit Too Expensive
Merck KGaA's stock remains a 'hold' due to its high valuation, trading at an earnings multiple of around 20 and a 4.5% free cash flow yield. Read why MKGAF is a hold.
Resilience is part of our DNA, says Merck KGaA CEO
Belén Garijo, CEO of Merck KGaA, said the German pharmaceutical company has increased its readiness to deal with the ongoing geopolitical uncertainty, and is confident it will continue delivering prof...

Merck KGaA (MKGAF) Q4 2024 Earnings Call Transcript
Merck KGaA (OTCPK:MKGAF) Q4 2024 Results Conference Call March 6, 2025 8:00 AM ET Company Participants Florian Schraeder - Head of Investor Relations Belen Garijo - Group CEO Helene von Roeder - Group...

Merck KGaA sees forex-adjusted earnings growth of up to 8% this year
Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor chemicals and for lab equipment in biotech drug production.

Merck KGaA to replace two executives with company veterans
Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new leadership from June but it added that its strategy remains unchanged.

Exclusive: Germany's Merck KGaA in talks to buy US cancer biotech firm Springworks, sources say
Merck KGaA , the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker Springworks Therapeutics , according to people familiar with the matter...

Merck KGaA says high asset prices call for prudent M&A approach
The CEO of Germany's Merck KGaA said a recovery in sales growth at its existing business means it can take a cautious approach when it comes to buying other companies, which are expensively priced.

Mirror Biologics Enters Clinical Collaboration with Merck KGaA, Darmstadt, Germany in Metastatic Colorectal Cancer
TAMPA, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Mirror Biologics, Inc., specializing in development and manufacturing of immunotherapy products where the active ingredient is living, non-genetically al...

Merck KGaA (MKGAF) Q3 2024 Earnings Call Transcript
Merck KGaA (OTCPK:MKGAF) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belen Lopez - Chair of Executive Board & CEO He...

Merck KGaA Q3 earnings rise faster than expected on lower costs
Merck KGaA on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by cost-cutting measures and temporarily lower spending on drug research and development.

Merck KGaA: A Continued Long-Term Upside Despite Some Lag
Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 was mixed-positive. Going into Q3 2024, I consider MKGAF to be an attracti...
AI is driving semiconductor industry, says CEO Electronics at Merck KgaA
Kai Beckmann, a member of the executive board and the CEO Electronics at Merck KgaA, discusses the use of AI in the semiconductor industry.

Merck KGaA Shares Jump on Expectations of AI Boost
The German company said booming artificial-intelligence demand would help its electronics sales grow faster than previously expected over the medium term.

Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the first patient has been dosed in the Phase III MyClad trial (NCT064635...

Merck KGaA (MKGAF) Q2 2024 Earnings Call Transcript
Merck KGaA (OTCPK:MKGAF) Q2 2024 Results Conference Call August 1, 2024 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belen Lopez - Chair of Executive Board & CEO Helene...

Merck KGaA: The Drop Makes The Upside All The Sweeter
Merck KGaA remains undervalued with strong fundamentals and diverse business portfolio in healthcare, life sciences, and electronics. The company has above-average margins compared to the broader mark...

Merck KGaA, Darmstadt, Germany, Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the discontinuation of the Phase III randomized TrilynX study evaluating ...

Merck to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced new research from the company's diverse oncology portfolio will be presented at the 2024 American ...

Merck KGaA (MKGAF) Q1 2024 Earnings Call Transcript
Merck KGaA (OTCPK:MKGAF) Q1 2024 Results Conference Call May 15, 2024 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belen Garijo - Chair & CEO Helene von Roeder - CFO Ma...

Merck KGaA's Q1 adjusted profit declines less than feared
Merck KGaA on Wednesday reported better-than-expected adjusted earnings, helped by strong demand for its pharmaceuticals and amid currency-adjusted sales growth in semiconductor materials.
We are expecting life sciences to be stronger in the second half of 2024, says Merck KGaA CEO
Belén Garijo, CEO of Merck KGaA, discusses full-year results and her outlook for the life sciences industry.

Merck KGaA (MKGAF) Q4 2023 Earnings Call Transcript
Merck KGaA (OTCPK:MKGAF) Q4 2023 Results Conference Call March 7, 2024 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belen Garijo - Chair & CEO Helene von Roeder - CFO M...

Merck KGaA forecasts return to organic earnings growth in 2024
Merck KGaA predicted a return to modest operating earnings growth, when adjusted for currency headwinds, citing a gradual recovery in demand for specialty materials that are used to make biotech drugs...
'Europe is lagging behind' on innovation: Merck KGaA CEO
Belén Garijo, CEO of science and technology company Merck KGaA, discusses European regulation, growth and innovation with CNBC at Davos.

4 Pharma Stocks to Buy, According to an Analyst. Novo Nordisk Isn't One.
Drug stocks GSK, Sanofi, Merck KGaA, and Novartis look set for a good year on strong cash flows and attractive valuations, says UBS.